Donor-derived CAR-T Cells in the Treatment of AML Patients

Inclusion Criteria: * Refractory or relapsed AML patients. * Have found an appropriate matched donor for CAR-T cells manufacturing. * Patients must have evaluable evidence of disease. * Age ≥ 18 years; Expected survival is more than 3 months. * ECOG score 0-2 points. * Women of childbearing age have negative blood pregnancy test before the start of the trial, and agree to take effective contraceptive measures during the trial until the last follow-up; male subjects with partners of childbearing potential agree to take effective contraceptive measures during the trial until the last follow-up. * Adequet liver, kidney, heart and lung function. Exclusion Criteria: * Confirmed acute promyelocytic leukemia; or recent symptomatic central nervous system leukemia. * Patients with graft-versus-host disease requiring the use of immunosuppressive agents; or patients with autoimmune system diseases. * Prior use of any gene therapy product. * History of epilepsy or other central nervous system diseases. * Presence of concurrent active malignancy. * Active hepatitis B or C virus, patients with HIV or syphilis infection. * Currently participating in or having participated in other drug clinical trials during past 30 days. * Active or uncontrolled infection requiring systemic therapy within 14 days prior to enrollment. * Other situations not suitable for the study judged by the investigator.